The Q10 reported $162 million in cash which will fund all business operations until fiscal Q2 2019. Plus add revenues from canine osteosarcoma tx once approved by the USDA to that total. That should cover us for the next two years.
We might well see 50mio OS before the company is being bought out or has final FDA approval. But still if the MC is 3B, then we are at $60, with the famous 6B, then $120, 10B makes $200...I could live with that... Question is timeframe and if 50mio OS is enough...